Transport screening of drug cocktails through an in vitro blood-brain barrier:: Is it a good strategy for increasing the throughput of the discovery pipeline?

被引:26
作者
Berezowski, V
Landry, C
Lundquist, S
Dehouck, L
Cecchelli, R
Dehouck, MP
Fenart, L [1 ]
机构
[1] Fac Jean Perrin, CELLIAL Technol, F-62303 Lens, France
[2] Fac Jean Perrin, Lab Mixte Univ Artois Inst Pasteur Lille, F-62307 Lens, France
[3] Astra Zeneca, S-15185 Sodertalje, Sweden
关键词
blood-brain barrier; drug screening; endothelial cells; in vitro; P-glycoprotein;
D O I
10.1023/B:PHAM.0000026424.78528.11
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. The objective of the current study was to investigate whether blood-brain barrier (BBB) permeability studies in vitro could be accelerated by running several compounds together in the same experiment. Methods. To address this question, we compared the transport of six compounds run separately with the results of the same compounds run together ( cocktails). Results. The study clearly demonstrated that the outcome of the experiments were totally different depending on the strategy used. Furthermore, the study highlights the importance of having the resistance to drug transport offered by filters without cells under control, as the filter membrane itself can be the rate-limiting step for some compounds; in addition, there is always a potential risk of interactions between molecules in cocktails as well as drug-drug interaction at the level of BBB transporters. In this study, the presence of several P-glycoprotein substrates in the drug cocktail was found to cause breakdown of the BBB. Conclusions. The results demonstrate that unless a strategy that involves running several compounds in the same experiment is properly validated, the results are of little predictive value.
引用
收藏
页码:756 / 760
页数:5
相关论文
共 23 条
[1]   NEUROLOGICAL SYMPTOMS AND COMA ASSOCIATED WITH DOXORUBICIN ADMINISTRATION DURING CHRONIC CYCLOSPORINE THERAPY [J].
BARBUI, T ;
RAMBALDI, A ;
PARENZAN, L ;
ZUCCHELLI, M ;
PERICO, N ;
REMUZZI, G .
LANCET, 1992, 339 (8806) :1421-1421
[2]  
BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97
[3]  
BORNSTEIN MB, 1958, LAB INVEST, V7, P134
[4]  
Bu HZ, 2000, RAPID COMMUN MASS SP, V14, P523, DOI 10.1002/(SICI)1097-0231(20000331)14:6<523::AID-RCM906>3.3.CO
[5]  
2-K
[6]   Toxicologic and pharmacokinetic study of low doses of verapamil combined with doxorubicin [J].
Candussio, L ;
Decorti, G ;
Crivellato, E ;
Granzotto, M ;
Rosati, A ;
Giraldi, W ;
Bartoli, F .
LIFE SCIENCES, 2002, 71 (26) :3109-3119
[7]   In vitro model for evaluating drug transport across the blood-brain barrier [J].
Cecchelli, R ;
Dehouck, B ;
Descamps, L ;
Fenart, L ;
Buée-Scherrer, V ;
Duhem, C ;
Lundquist, S ;
Rentfel, M ;
Torpier, G ;
Dehouck, MP .
ADVANCED DRUG DELIVERY REVIEWS, 1999, 36 (2-3) :165-178
[8]   Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice [J].
Cisternino, S ;
Rousselle, C ;
Dagenais, C ;
Scherrmann, JM .
PHARMACEUTICAL RESEARCH, 2001, 18 (02) :183-190
[9]   Drug transport to the brain: Comparison between in vitro and in vivo models of the blood-brain barrier [J].
Dehouck, MP ;
Dehouck, B ;
Schluep, C ;
Lemaire, M ;
Cecchelli, R .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 3 (06) :357-365
[10]   DRUG TRANSFER ACROSS THE BLOOD-BRAIN-BARRIER - CORRELATION BETWEEN INVITRO AND INVIVO MODELS [J].
DEHOUCK, MP ;
JOLLIETRIANT, P ;
BREE, F ;
FRUCHART, JC ;
CECCHELLI, R ;
TILLEMENT, JP .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (05) :1790-1797